Skip to main content

Table 2 Timing of measurements and outline of primary and secondary outcome measures

From: The effect of glucosamine sulphate on osteoarthritis: design of a long-term randomised clinical trial [ISRCTN54513166]

 

0 m

B.A.

3 m

Q

6 m

Visit

9 m

Q

12 m

Visit

15 m

Q

18 m

Visit

21 m

Q

24 m

F.A.

Primary outcome measures

         

Joint space width

x

       

x

Pain score (WOMAC)

x

       

x

Function score (WOMAC)

x

       

x

Secondary outcome measures

         

Subchondral bone quality

x

       

x

Stiffness score (WOMAC)

x

x

x

x

x

x

x

x

x

Quality of life (EuroQol EQ-5D)

x

x

x

x

x

x

x

x

x

Medical consumption

x

x

x

x

x

x

x

x

x

Side effects

 

x

x

x

x

x

x

x

x

CTX-II

x

 

x

 

x

 

x

 

x

Possible confounders/Effect modifiers

         

Type of OA (localised – generalised)

x

        

Radiological severity

x

       

x

Joint function

x

       

x

Age

x

        

Gender

x

        

Activity level

x

x

x

x

x

x

x

x

x

Co-interventions

x

x

x

x

x

x

x

x

x

Compliance (BMQ)

 

x

x

x

x

x

x

x

x

Compliance (pill count)

  

x

 

x

 

x

 

x

  1. Note: 0 m: 0 month of follow up, 3 m: 3 months of follow up etc. B.A.: baseline assessment. Visit: 6 monthly visit. F.A.: final assessment
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us